Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXP900 in Advanced Cancers
NCT05873686Phase 1Active, not recruiting
- Sponsor
- Nuvectis Pharma, Inc.
- Start
- Oct 2023
- Primary completion
- Mar 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of NXP900 in solid tumor, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by Nuvectis Pharma, Inc. Primary endpoints: Treatment related adverse events and/or clinical laboratory abnormalities at 30 days, Dose Limiting Toxicities at 28 days and 3 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
NXP900
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)mesothelioma
Beyond the preview
Go deeper on NCT05873686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873686.